胎龄&lt;34周早产儿一氧化氮吸入的研究进展

梁国宝; 林新祝

doi:10.7499/j.issn.1008-8830.2303146

PDF(551 KB)

HTML

中国当代儿科杂志 ›› 2023, Vol. 25 ›› Issue (9) : 982-988. DOI: 10.7499/j.issn.1008-8830.2303146

综述

胎龄<34周早产儿一氧化氮吸入的研究进展

梁国宝, 林新祝

作者信息 +

Recent research on inhaled nitric oxide in preterm infants with a gestational age of <34 weeks

LIANG Guo-Bao, LIN Xin-Zhu

Author information +

文章历史 +

摘要

一氧化氮作为血管平滑肌细胞舒张的信使分子，吸入一氧化氮（inhaled nitric oxide, iNO）能够扩张肺部血管，降低肺血管阻力，从而降低肺动脉压力，而对体循环压力没有影响。国内外指南均推荐iNO用于足月儿和晚期早产儿，已证实对足月儿和晚期早产儿持续肺动脉高压和低氧性呼吸衰竭具有明显效果。但是近年来的研究显示，iNO用于胎龄<34周早产儿的超适应证治疗越来越多。该文就iNO治疗胎龄<34周早产儿的有效性、安全性、应用时机、剂量、撤离方式和与血管活性药物联合使用的国内外研究进展作一综述，以期为临床应用提供参考。

Abstract

Nitric oxide is a messenger molecule for vasodilation of vascular smooth muscle cells, and inhaled nitric oxide (iNO) can dilate pulmonary blood vessels and reduce pulmonary vascular resistance, thereby reducing pulmonary artery pressure, but with no influence on systemic circulation pressure. Guidelines in China and overseas recommend the use of iNO in full-term infants and late preterm infants, and it has been proved that it has a marked effect on persistent pulmonary hypertension and hypoxic respiratory failure in such infants. However, recent studies have shown that there is an increase in the off-label use of iNO in preterm infants with a gestational age of <34 weeks. This article reviews the research progress on the efficacy, safety, timing, dose, and withdrawal mode of iNO and its combination with vasoactive drugs in the treatment of preterm infants with a gestational age of <34 weeks in China and overseas, so as to provide a reference for clinical application.

导出引用

梁国宝, 林新祝. 胎龄<34周早产儿一氧化氮吸入的研究进展[J]. 中国当代儿科杂志. 2023, 25(9): 982-988 https://doi.org/10.7499/j.issn.1008-8830.2303146

LIANG Guo-Bao, LIN Xin-Zhu. Recent research on inhaled nitric oxide in preterm infants with a gestational age of <34 weeks[J]. Chinese Journal of Contemporary Pediatrics. 2023, 25(9): 982-988 https://doi.org/10.7499/j.issn.1008-8830.2303146

参考文献

1 Yu B, Ichinose F, Bloch DB, et al. Inhaled nitric oxide[J]. Br J Pharmacol, 2019, 176(2): 246-255. PMID: 30288739. PMCID: PMC6295404. DOI: 10.1111/bph.14512.
2 Singh Y, Lakshminrusimha S. Pathophysiology and management of persistent pulmonary hypertension of the newborn[J]. Clin Perinatol, 2021, 48(3): 595-618. PMID: 34353582. PMCID: PMC8351908. DOI: 10.1016/j.clp.2021.05.009.
3 Suzuki S, Togari H, Potenziano JL, et al. Efficacy of inhaled nitric oxide in neonates with hypoxic respiratory failure and pulmonary hypertension: the Japanese experience[J]. J Perinat Med, 2018, 46(6): 657-663. PMID: 28926340. DOI: 10.1515/jpm-2017-0040.
4 Barrington KJ, Finer N, Pennaforte T, et al. Nitric oxide for respiratory failure in infants born at or near term[J]. Cochrane Database Syst Rev, 2017, 1(1): CD000399. PMID: 28056166. PMCID: PMC6464941. DOI: 10.1002/14651858.CD000399.pub3.
5 American Academy of Pediatrics. Committee on Fetus and Newborn. Use of inhaled nitric oxide[J]. Pediatrics, 2000, 106(2 Pt 1): 344-345. PMID: 10920164.
6 刘俊佐, 郑荣秀, 阚璇, 等. 吸入一氧化氮在早产儿疾病的应用研究进展[J]. 中国小儿急救医学, 2021, 28(11): 998-1001. DOI: 10.3760/cma.j.issn.1673-4912.2021.11.013.
7 Cole FS, Alleyne C, Barks JD, et al. NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants[J]. Pediatrics, 2011, 127(2): 363-369. PMID: 21220405. DOI: 10.1542/peds.2010-3507.
8 Kumar P, Committee on Fetus and Newborn, American Academy of Pediatrics. Use of inhaled nitric oxide in preterm infants[J]. Pediatrics, 2014, 133(1): 164-170. PMID: 24379225. DOI: 10.1542/peds.2013-3444.
9 Vieira F, Makoni M, Szyld E, et al. The controversy persists: is there a qualification criterion to utilize inhaled nitric oxide in pre-term newborns?[J]. Front Pediatr, 2021, 9: 631765. PMID: 33869113. PMCID: PMC8044816. DOI: 10.3389/fped.2021.631765.
10 Udland CJ, Carey WA, Weaver AL, et al. Birth size and gestational age specific outcomes of inhaled nitric oxide therapy in preterm neonates with clinically diagnosed pulmonary hypertension[J]. Am J Perinatol, 2019, 36(14): 1471-1480. PMID: 30674051. DOI: 10.1055/s-0039-1677799.
11 Subhedar NV, Jawad S, Oughham K, et al. Increase in the use of inhaled nitric oxide in neonatal intensive care units in England: a retrospective population study[J]. BMJ Paediatr Open, 2021, 5(1): e000897. PMID: 33705500. PMCID: PMC7903123. DOI: 10.1136/bmjpo-2020-000897.
12 Peluso AM, Othman HF, Karnati S, et al. Epidemiologic evaluation of inhaled nitric oxide use among neonates with gestational age less than 35 weeks[J]. Pediatr Pulmonol, 2022, 57(2): 427-434. PMID: 34842352. DOI: 10.1002/ppul.25775.
13 Nakanishi H, Isayama T, Kokubo M, et al. Inhaled nitric oxide therapy in the post-acute phase in extremely preterm infants: a Japanese cohort study[J]. J Pediatr, 2023, 252: 61-67.e5. PMID: 36116533. DOI: 10.1016/j.jpeds.2022.07.057.
14 Oka S, Nishimura E, Ozawa J, et al. Therapeutic response of iNO in preterm infants with hypoxemic respiratory failure[J]. Pediatr Int, 2023, 65(1): e15423. PMID: 36412230. DOI: 10.1111/ped.15423.
15 刘畅, 张舒晴, 岳冬梅. 吸入一氧化氮治疗新生儿持续肺动脉高压的研究进展[J]. 中国小儿急救医学, 2019, 26(11): 858-862. DOI: 10.3760/cma.j.issn.1673-4912.2019.11.011.
16 Hsiao HF, Yang MC, Lai MY, et al. The off-label use of inhaled nitric oxide as a rescue therapy in neonates with refractory hypoxemic respiratory failure: therapeutic response and risk factors for mortality[J]. J Clin Med, 2019, 8(8): 1113. PMID: 31357613. PMCID: PMC6722605. DOI: 10.3390/jcm8081113.
17 Busè M, Graziano F, Lunetta F, et al. Inhaled nitric oxide as a rescue therapy in a preterm neonate with severe pulmonary hypertension: a case report[J]. Ital J Pediatr, 2018, 44(1): 55. PMID: 29764471. PMCID: PMC5952598. DOI: 10.1186/s13052-018-0494-9.
18 Shiraishi J, Kusuda S, Cho K, et al. Standardization of nitric oxide inhalation in extremely preterm infants in Japan[J]. Pediatr Int, 2019, 61(2): 152-157. PMID: 30523661. DOI: 10.1111/ped.13746.
19 Dani C, Corsini I, Cangemi J, et al. Nitric oxide for the treatment of preterm infants with severe RDS and pulmonary hypertension[J]. Pediatr Pulmonol, 2017, 52(11): 1461-1468. PMID: 29058384. DOI: 10.1002/ppul.23843.
20 Van Meurs KP, Wright LL, Ehrenkranz RA, et al. Inhaled nitric oxide for premature infants with severe respiratory failure[J]. N Engl J Med, 2005, 353(1): 13-22. PMID: 16000352. DOI: 10.1056/NEJMoa043927.
21 Hascoet JM, Fresson J, Claris O, et al. The safety and efficacy of nitric oxide therapy in premature infants[J]. J Pediatr, 2005, 146(3): 318-323. PMID: 15756211. DOI: 10.1016/j.jpeds.2004.10.019.
22 Boly TJ, Dagle JM, Klein JM, et al. Response categorization and outcomes in extremely premature infants born at 22-26 weeks gestation that received inhaled nitric oxide for hypoxic respiratory failure[J]. J Perinatol, 2023, 43(3): 324-331. PMID: 36509816. PMCID: PMC10173872. DOI: 10.1038/s41372-022-01582-4.
23 Rallis D, Deierl A, Atreja G, et al. The efficacy of inhaled nitric oxide treatment in premature infants with acute pulmonary hypertension[J]. Early Hum Dev, 2018, 127: 1-5. PMID: 30205295. DOI: 10.1016/j.earlhumdev.2018.09.004.
24 Barrington KJ, Finer N, Pennaforte T. Inhaled nitric oxide for respiratory failure in preterm infants[J]. Cochrane Database Syst Rev, 2017, 1(1): CD000509. PMID: 28045472. PMCID: PMC6464861. DOI: 10.1002/14651858.CD000509.pub5.
25 Chandrasekharan P, Lakshminrusimha S, Abman SH. When to say no to inhaled nitric oxide in neonates?[J]. Semin Fetal Neonatal Med, 2021, 26(2): 101200. PMID: 33509680. DOI: 10.1016/j.siny.2021.101200.
26 Sherlock LG, Wright CJ, Kinsella JP, et al. Inhaled nitric oxide use in neonates: balancing what is evidence-based and what is physiologically sound[J]. Nitric Oxide, 2020, 95: 12-16. PMID: 31866361. PMCID: PMC7594166. DOI: 10.1016/j.niox.2019.12.001.
27 Sakaria RP, Dhanireddy R. Pharmacotherapy in bronchopulmonary dysplasia: what is the evidence?[J]. Front Pediatr, 2022, 10: 820259. PMID: 35356441. PMCID: PMC8959440. DOI: 10.3389/fped.2022.820259.
28 Muehlbacher T, Bassler D, Bryant MB. Evidence for the management of bronchopulmonary dysplasia in very preterm infants[J]. Children (Basel), 2021, 8(4): 298. PMID: 33924638. PMCID: PMC8069828. DOI: 10.3390/children8040298.
29 Manja V, Guyatt G, Lakshminrusimha S, et al. Factors influencing decision making in neonatology: inhaled nitric oxide in preterm infants[J]. J Perinatol, 2019, 39(1): 86-94. PMID: 30353082. PMCID: PMC6298829. DOI: 10.1038/s41372-018-0258-9.
30 Alvarado Socarras JL, Monsalve JC, Diaz Quijano FA. Inhaled nitric oxide in preterm neonates with refractory hypoxemia associated to oligohydramnios[J]. Curr Drug Discov Technol, 2018, 15(2): 156-160. PMID: 29046161. DOI: 10.2174/1570163814666171017162730.
31 Mullaly R, McCallion N, El-Khuffash A. Inhaled nitric oxide in preterm neonates with preterm prelabour rupture of membranes, a systematic review[J]. Acta Paediatr, 2023, 112(3): 358-371. PMID: 36377399. DOI: 10.1111/apa.16596.
32 Kinsella JP, Cutter GR, Walsh WF, et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure[J]. N Engl J Med, 2006, 355(4): 354-364. PMID: 16870914. DOI: 10.1056/NEJMoa060442.
33 王子鸣, 李欢欢, 史源. 胎龄≤34周需呼吸支持早产儿吸入一氧化氮疗效的Meta分析[J]. 中华新生儿科杂志, 2021, 36(4): 53-58. DOI:10.3760/cma.j.issn.2096-2932.2021.04.012.
34 Schreiber MD, Gin-Mestan K, Marks JD, et al. Inhaled nitric oxide in premature infants with the respiratory distress syndrome[J]. N Engl J Med, 2003, 349(22): 2099-2107. PMID: 14645637. DOI: 10.1056/NEJMoa031154.
35 Su PH, Chen JY. Inhaled nitric oxide in the management of preterm infants with severe respiratory failure[J]. J Perinatol, 2008, 28(2): 112-116. PMID: 17989696. DOI: 10.1038/sj.jp.7211881.
36 Zheng Y, Wu Q, Han S. Inhaled nitric oxide in premature infants for preventing bronchopulmonary dysplasia: a meta-analysis[J]. BMC Pediatr, 2023, 23(1): 139. PMID: 36991371. PMCID: PMC10053486. DOI: 10.1186/s12887-023-03923-4.
37 Garrido F, Gonzalez-Caballero JL, Lomax R, et al. The immediate efficacy of inhaled nitric oxide treatment in preterm infants with acute respiratory failure during neonatal transport[J]. Acta Paediatr, 2020, 109(2): 309-313. PMID: 31373038. DOI: 10.1111/apa.14958.
38 马群英, 董文斌. 吸入一氧化氮防治早产儿支气管肺发育不良的Meta分析[J]. 中国医药科学, 2016, 6(3): 49-52.
39 DiBlasi RM, Myers TR, Hess DR. Evidence-based clinical practice guideline: inhaled nitric oxide for neonates with acute hypoxic respiratory failure[J]. Respir Care, 2010, 55(12): 1717-1745. PMID: 21122181.
40 Mandell E, Kinsella JP, Abman SH. Persistent pulmonary hypertension of the newborn[J]. Pediatr Pulmonol, 2021, 56(3): 661-669. PMID: 32930508. DOI: 10.1002/ppul.25073.
41 Pedersen J, Hedegaard ER, Simonsen U, et al. Current and future treatments for persistent pulmonary hypertension in the newborn[J]. Basic Clin Pharmacol Toxicol, 2018, 123(4): 392-406. PMID: 29855164. DOI: 10.1111/bcpt.13051.
42 Dillard J, Pavlek LR, Korada S, et al. Worsened short-term clinical outcomes in a cohort of patients with iNO-unresponsive PPHN: a case for improving iNO responsiveness[J]. J Perinatol, 2022, 42(1): 37-44. PMID: 34654904. PMCID: PMC8518280. DOI: 10.1038/s41372-021-01228-x.
43 Lakshminrusimha S, Keszler M. Persistent pulmonary hypertension of the newborn[J]. Neoreviews, 2015, 16(12): e680-e692. PMID: 26783388. PMCID: PMC4714607. DOI: 10.1542/neo.16-12-e680.
44 Sharma V, Berkelhamer S, Lakshminrusimha S. Persistent pulmonary hypertension of the newborn[J]. Matern Health Neonatol Perinatol, 2015, 1: 14. PMID: 27057331. PMCID: PMC4823682. DOI: 10.1186/s40748-015-0015-4.
45 方赛, 杜立中. 新生儿持续性肺动脉高压的治疗进展[J]. 中华重症医学电子杂志（网络版）, 2019, 5(3): 268-273.
46 李令雪, 魏兵, 杨明, 等. 波生坦治疗新生儿持续性肺动脉高压有效性及安全性的Meta分析[J]. 中国当代儿科杂志, 2022, 24(3): 319-325. PMID: 35351265. PMCID: PMC8974651. DOI: 10.7499/j.issn.1008-8830.2109151.
47 Centorrino R, Shankar-Aguilera S, Foligno S, et al. Life-threatening extreme methemoglobinemia during standard dose nitric oxide therapy[J]. Neonatology, 2019, 116(3): 295-298. PMID: 31454813. DOI: 10.1159/000501462.
48 中国医师协会新生儿科医师分会. 一氧化氮吸入治疗在新生儿重症监护病房的应用指南（2019版）[J]. 发育医学电子杂志, 2019, 7(4): 241-248. DOI: 10.3969/j.issn.2095-5340.2019.04.001.
49 Chandrasekharan P, Lakshminrusimha S, Chowdhury D, et al. Early hypoxic respiratory failure in extreme prematurity: mortality and neurodevelopmental outcomes[J]. Pediatrics, 2020, 146(4): e20193318. PMID: 32943536. PMCID: PMC7546092. DOI: 10.1542/peds.2019-3318.